Poolbeg Pharma Ltd. (GB:POLB) has released an update.
Poolbeg Pharma Ltd. has announced the granting of a significant US patent for POLB 001, a drug targeting hypercytokinaemia, which is a key factor in cytokine storms across various diseases. This development strengthens the company’s intellectual property portfolio and increases the drug’s appeal to potential pharmaceutical partners. CEO Jeremy Skillington expressed confidence in POLB 001’s promise for treating severe influenza and immunotherapy-induced cytokine release syndrome, highlighting its potential to address unmet medical needs and its substantial market opportunity.
For further insights into GB:POLB stock, check out TipRanks’ Stock Analysis page.
